Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
molidustat
- Development stage
- Phase 3
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Molidustat is a small molecule drug that acts as a competitive and reversible inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH). By inhibiting HIF-PH, molidustat stabilizes hypoxia-inducible factors (HIFs), leading to increased endogenous production of erythropoietin (EPO) and subsequent stimulation of erythropoiesis (red blood cell production). It is primarily developed for the treatment of anemia associated with chronic kidney disease, both in humans and veterinary medicine. In cats, it is conditionally approved by the FDA under the brand name Varenzin-CA1 for controlling nonregenerative anemia due to chronic kidney disease. Molidustat has also been investigated in clinical trials for renal anemia in non-dialysis human subjects[3][4][5][6][7].
- Brand names
- Varenzin-CA1Varenzin-CA-1Varenzin-CA 1
- Other names
- molidustat
02
Targets
PHD1 (Prolyl hydroxylase domain-containing protein 1)PHD3 (Prolyl hydroxylase domain-containing protein 3)EGLN1 (Prolyl hydroxylase domain-containing protein 2)FIH-1 (Factor inhibiting hypoxia-inducible factor 1)
Beyond the preview
Go deeper on molidustat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on molidustat.